Biotech

NEXT Life Sciences Secures $2.5M in Funding to Advance Male Contraceptive Product Plan A

NEXT Life Sciences, the creator of the male contraceptive product Plan A, recently announced a successful $2.5 million funding round to advance the launch of its innovative solution into the market. The Family, a high-impact startup accelerator led the round with participation from Transform VC and a combination of angel investors and early-stage venture funds including entrepreneur Brock Pierce, Transform VC, StartupHealth, Pay…

Illumina Ventures Labs Launches to Accelerate Genomics Startups in the US and UK

Illumina Ventures Labs, an incubator for early-stage genomics and precision health companies, has officially launched operations in Foster City, California, and Cambridge, United Kingdom. The venture, part of Illumina Ventures, aims to nurture the growth of start-ups in the healthcare sector, particularly those focusing on genomics. Illumina Ventures Labs is finalizing agreements with several startups, providing them access to advanced genomics laboratories…

Daré Bioscience Advances DARE-LARC1 Drug Delivery Platform for Women’s Health

Daré Bioscience, a biopharma company specializing in women’s health, has announced the development of DARE-LARC1, a drug delivery platform that can administer therapeutic doses over extended periods. This platform is designed to store and precisely deliver medications for months or years through a single device. The technology behind DARE-LARC1, developed initially at the Massachusetts Institute of Technology by Drs. Robert Langer and…

Pearsanta Acquires MDNA’s Mitomic Platform for Endometriosis and Ovarian Cancer Detection for $25M

Pearsanta, a subsidiary of Aditxt, has recently acquired the Mitomic testing platform from MDNA Life Sciences. The transaction, valued at approximately $25 million, is a strategic expansion for Pearsanta, enhancing its capabilities in early disease and cancer detection, particularly in women’s health, focusing on conditions such as endometriosis and ovarian cancer. The Mitomic technology utilizes mitochondrial DNA (mtDNA) to detect diseases at…

Qvin’s Q-Pad Makes History with First FDA Approval for Menstrual Blood Health Testing

Biotech research company Qvin has announced the FDA clearance of its innovative Q-Pad and A1c Test, marking a significant advancement in women’s health technology. This approval introduces a new method of health monitoring for millions of American women, particularly those living with diabetes, through menstrual blood testing. The Q-Pad offers a less invasive and more accessible alternative to traditional venous blood draws.…

Heranova Raises $13.5M for Novel Non-Invasive Diagnostics and Treatment of Endometriosis and Bacterial Vaginosis

Heranova Lifesciences has announced the completion of a $13.5M seed and seed+ financing round to develop and offer integrated women’s health solutions. The fresh funds will go towards the launch of non-invasive endometriosis tests and advance two innovative (non-hormonal and non-antibiotic) therapeutic programs for endometriosis and bacterial vaginosis. Institutional investors including Pivotal bioVenture Partners China, Sinovation Ventures, Emerging Technology Partners, and Triwise Capital…

Hera Biotech to Acquire Endometriosis Diagnostic Assets from Scailyte in Move Towards Non-Surgical Diagnosis

In a stride towards non-surgical endometriosis diagnosis, Hera Biotech has announced its impending acquisition of endometriosis diagnostic assets from Scailyte, a company active in single-cell and AI-driven biomarker discovery. This acquisition marks a notable consolidation in the tissue-based diagnostic landscape for endometriosis, a prevalent condition contributing to a significant portion of female infertility and characterized by severe pain due to the abnormal…

Orchid Introduces Whole Genome Sequencing Reports for Embryos After Raising $12M in Funding

Orchid, a reproductive technology company, has announced the introduction of the world’s first 30x whole genome sequencing reports for embryos. This innovation, supported by a $12M in total funding, is set to provide prospective parents with unprecedented insights into the genetic health of embryos. Orchid’s investors include Prometheus Fund, Starbloom Capital, Refactor Capital, Pebblebed, Day One Ventures, and Conviction Capital, as well…